METHOD OF TREATING GRAFT VERSUS HOT DISEASE
A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1 bright cells and/or progeny thereof and/or soluble factors derived therefrom.
1 . A method for preventing the development of or treating GvHD complications in a patient which comprises administering to the mammal a population of cells enriched for STRO-1 bright cells and/or progeny thereof.
2 . A method for preventing the development of or treating GvHD complications in a patient which comprises administering to the mammal a population of cells enriched for STRO-1 bright cells and/or progeny thereof.
3 . The method according to claim 2 , wherein the population of cells enriched for STRO-1 bright cells and/or progeny cells thereof is administered to the patient prior to administration of the precursors of bone marrow lineage cells.
4 . The method according to claim 2 , wherein the population of cells enriched for STRO-1 bright cells and/or progeny cells thereof is co-administered with the precursors of bone marrow lineage cells.
5 . The method according to claim 2 , wherein the precursors of bone marrow lineage cells are allogeneic cells administered to the mammal to treat a malignant or genetic disease of the blood.
6 . The method according to claim 1 wherein the STRO-1 bright cells and/or progeny thereof are allogeneic.
7 . The method according to claim 1 wherein the population of cells enriched for STRO-1 bright cells and/or progeny cells thereof is administered systemically.
8 . The method according to claim 7 , wherein the population of cells enriched for STRO-1 bright cells and/or progeny cells thereof is administered by intravenous injection.
9 . The method of claim 1 , comprising administering from 0.1×10 6 to 5×10 6 STRO-1 bright cells and/or progeny thereof.
10 . The method of claim 1 , comprising administering from 0.3×10 6 to 2×10 6 STRO-1 bright cells and/or progeny thereof.
11 . The method of claim 1 comprising administering a low dose of STRO-1 bright cells and/or progeny thereof.
12 . The method of claim 11 , wherein the low dose of STRO-1 bright cells and/or progeny thereof comprises between 0.1×10 5 and 0.5×10 6 STRO-1 bright cells and/or progeny thereof.
13 . The method of claim 11 , wherein the low dose of STRO-1 bright cells and/or progeny thereof comprises about 0.3×10 6 STRO-1 bright cells and/or progeny thereof.
14 . The method of claim 1 , wherein the population enriched for STRO-1 bright cells and/or progeny thereof is administered once weekly or less often.
15 . The method according to claim 1 , wherein the mammal is suffering from aplastic anemia, myelofibrosis, or bone marrow failure following chemotherapy and radiation therapy.
16 . The method according to claim 1 , further comprising administering an immunosuppressive drug to the mammal.